Objective: Dickkopf-related protein 1 (DKK1) is a soluble antagonist of the Wningless (Wnt) pathway. It binds to and sequesters low-density lipoprotein receptor-related proteins 5/6 away from Wnts. Because the Wnt pathway regulates synaptic transmission and plasticity, we hypothesized that increased DKK1 would increase the risk for neurocognitive impairment (NCI) in HIV-positive (HIV þ ) individuals. We evaluated, here, the relationship between plasma DKK1 and global NCI.
Introduction
The introduction of combined antiretroviral therapy (ART) transformed HIV to a chronic disease with several potential complications, one of which is HIV-associated neurocognitive disorder (HAND). HAND refers to a spectrum of neurocognitive impairments associated with HIV neuroinvasion and neuroinflammation that leads to impairment in attention, memory, language, problem solving, and decision-making, which significantly impacts day-to-day function [1] . The spectrum of impairments includes asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia. Even when ART suppresses HIV RNA, HAND can still affect up to 50% of HIV positive (HIV þ ) adults [2, 3] and its prevalence is expected to increase with aging. This underscores the need to define biomarkers that can accurately predict the chance for developing HAND, reveal mechanisms that drive HAND, and ultimately devise novel strategies to prevent and/or treat HAND.
We assessed whether a molecule related to Wnt signaling is a clinical biomarker of HAND. The Wnt pathway plays critical roles in the developing [4] and adult brain [5] , including regulation of synaptogenesis and plasticity [6] . Wnts are a family of 19 highly conserved, small secreted glycoproteins that bind to the seven-transmembrane Frizzled receptors and its coreceptor, low-density lipoprotein receptor-related proteins 5 and 6 (LRP 5/6), to engage a signaling cascade that culminates in b-catenin-dependent or independent signaling. Downstream genes of the Wnt pathway play critical roles in cell communication, cell cycle, cell survival, cell renewal/ stemness, differentiation, and organogenesis, to name a few [7, 8] . Dysregulation in Wnt signaling has been linked to neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease [6, 7] . We established that Wnt/b-catenin is a restriction factor for HIV in astrocytes, monocytes, and T cells, and elucidated the relevant molecular mechanisms [9] [10] [11] [12] [13] [14] . We also established that inhibition of b-catenin has a dramatic effect on the ability of astrocytes to scavenge for glutamate by inhibiting the expression of excitatory amino acid transporter 2 (EAAT-2/GLT-1 in rodents) and glutamine synthetase [15] . Our working model is that signals that diminish Wnt/b-catenin will compromise brain homeostasis and contribute to HAND.
Because b-catenin is an intracellular protein, it is not an ideal biomarker candidate. For this reason, we turned to dickkopf-related protein 1 (DKK1). DKK1 is a secreted soluble antagonist of the Wnt pathway. It binds to the coreceptor of Wnts, LRP 5/6 and sequesters it away from Wnts. We showed that an inflammatory signal (e.g. interferon-g) inhibits Wnt/b-catenin signaling in astrocytes through induction of DKK1 in a Signal Transducers and Activators of Transcription (STAT)3-dependent manner [12] . Recent studies demonstrate that DKK1 induces the rapid disassembly of synapses in mature neurons, and it mediates synaptic loss induced by amyloid-b [16] . These emerging studies point to a relationship between DKK1 and neurodegenerative disorders. We assessed, here, whether DKK1 levels in plasma are associated with worse global neurocognitive performance in a cohort of HIV þ and HIV-negative (HIV -) adults.
Methods
Human research ethical statement The study was conducted in accordance with the declaration of Helsinki. The Human Research Protections Programs of the University of California San Diego and Rush University Medical Center approved the human rights and protection aspects of the study and all participants provided written, informed consent.
Patient and sample selection Participants were recruited as part of the Translational Methamphetamine AIDS Research Center project, an ongoing multidisciplinary investigation of the effects of HIV infection and methamphetamine abuse on neurocognitive performance and other outcomes. HIV status and seronegative status for hepatitis C virus were confirmed by immunoassay (MedMira Inc., Nova Scotia, Canada). Blood was collected by standard methods and current CD4 þ T-cell count (cells/ml) was determined by flow cytometry at a Clinical Laboratory Improvement Amendments-certified lab. HIV RNA levels were measured in plasma by reverse transcriptase PCR (Roche Amplicor, Indianapolis, Indiana, USA; v. 1.5, lower limit of assay at least 50 copies/ml). Nadir CD4 þ T-cell count and duration of HIV disease were obtained by self-report.
Eligible participants were at least 18 years of age, without a prior head injury resulting in loss of consciousness for more than 30 min; previous cerebrovascular event; or a prior or current seizure disorder, or demyelinating disease. Chronic renal or pulmonary disease or other medical conditions that could confound neurocognitive performance also were exclusionary. Exclusion criteria also included lifetime diagnosis of schizophrenia or other psychotic disorder, as assessed with the Composite International Diagnostic Interview (version 2.1; Kessler and Ustun, 2004) [17] using Diagnostic and Statistical Manual of Mental Disorders-IV criteria (American Psychiatric Association, 2000).
Neurocognitive testing
All study participants were assessed using a standardized comprehensive neurocognitive test battery that assessed seven cognitive domains and adhered to recommended guidelines [18] . Neurocognitive performance was summarized using the global deficit score (GDS) method. GDS was calculated for each participant based on demographically corrected T-scores. The battery and its GDS summary score have previously demonstrated sensitivity to the effects of HIV on neuropsychological performance [19] .
Dickkopf-related protein 1 and monocyte chemoattractant protein-1 immunoassays
The plasma samples were diluted four times with calibrator diluent and DKK1 amount measured in duplicates using the Human DKK1 Quantikine ELISA Kit (DKK100), according to the manufacturer's instructions (R&D Systems, Minneapolis, Minnesota, USA). Bound DKK1 signal was developed with 100 ml of tetramethylbenzemidine microwell peroxidase substrate system (KPL, #50-76-00). The reaction was stopped with addition of 100 ml 1 mol/l H 3 PO 4 . The optical density was acquired in a microplate reader set to 450 nm and a correct set to 540 nm. DKK1 levels were calculated from a standard curve generated from DKK1 standard in the same plate. Human plasma monocyte chemoattractant protein-1 (MCP-1) levels were similarly measured using human MCP-1 Quantikine ELISA Kit (DCP00, R&D Systems, Minneapolis, Minnesota, USA) per manufacturer's instruction.
Statistical analysis
Data distributions were inspected and transformed as necessary to improve symmetry. For example, log 10 -transformed DKK1 concentrations were used in analyses. Comparisons were made using linear (e.g., continuous GDS) or logistic (e.g. binary NCI) regression. Planned stratified analyses were performed based on HIV serostatus (HIV þ vs. HIV À ) and HIV RNA suppression (HIV RNA 50 copies/ml vs. HIV RNA >50 copies/ ml). As the small number of HIV þ participants limited use of multivariate regression in this subgroup, the influence of individual covariates was evaluated by analysis of covariance. Considering the limited power of this analysis, no adjustment for type I error was imposed.
Results
Demographic and clinical characteristic of study participants In total, 83 participants were included: 41 HIV þ and 42 HIV À adults between the ages of 18 and 68 (Table 1) . In total, 26 of the HIV þ participants were maximally suppressed. The HIV þ and HIV À groups did not differ in age, ethnicity, education, illicit drugs such as methamphetamine dependence, or hepatitis C virus serostatus (Table 1) . Among HIV þ adults, NCI was associated with AIDS, ART use, and a trend toward lower nadir CD4 þ T-cell count (Table 1) .
Plasma dickkopf-related protein 1 levels are higher among HIV R participants with neurocognitive impairment Plasma DKK1 levels did not differ by HIV serostatus (656.7 vs. 598.0 pg/ml; P ¼ 0.54; Fig. 1a) . Plasma DKK1 levels also did not differ by neurocognitive performance among the combined HIV þ and HIV À groups, either when expressed as continuous GDS (P ¼ 0.46) or binary NCI (Fig. 1b) . Planned stratified analyses identified that DKK1 levels did differ by NCI among HIV þ participants (mean 813 pg/ml vs. 549 pg/ml, P < 0.05; Fig. 1c) , particularly those taking ART with HIV RNA levels 50 copies/ml or less (d ¼ 0.74, P ¼ 0.079; Fig. 1d ). In this subgroup, a receiver operator characteristic curve identified that DKK1 levels at least 735 pg/ml were highly specific for NCI (specificity 92.3%, odds ratio ¼ 7.5, P ¼ 0.054, Fig. 2 ) with high positive predictive value (83.3%), although DKK1 levels were not sensitive for detecting NCI (38.5%). Analysis of covariance identified that the relationship between the binary DKK1 variable and NCI was not significantly weakened by accounting for the covariance of AIDS status, nadir or current CD4 þ T-cell count, addictive drug use variables, age, sex, or ethnicity (data not shown).
Among the 26 HIV
þ study participants with maximally suppressed viral load, 20 had plasma DKK1 level less than 735 pg/ml and six had DKK1 more than 735 pg/ml. We compared this DKK1 cut point (735 pg/ml) among the 26 study participants to the variables listed in Table 1 and found an associations with age whereby those with DKK1 less than 735 pg/ml were younger (P ¼ 0.038; data not shown). A trend toward a lower duration of current ART regimen also emerged among those maximally suppressed with DKK1 less than 735 pg/ml, which did not reach significance (P ¼ 0.67). Nonetheless, adjusting for age and duration of current ART regimen did not weaken the association between DKK1 and NCI among virally suppressed study participants (data not shown).
Among the seven cognitive domains that were assessed, higher DKK1 levels were specifically associated with worse working memory (d ¼ 0.77, P ¼ 0.05). P values for comparisons with impaired performance in other domains were less than 0.20 except for motor perform-
Plasma monocyte chemoattractant protein-1 is higher among HIV R than HIV -study participants, but is not associated with neurocognitive status MCP1 is a soluble chemoattractant protein that is produced by activated astrocytes to recruit monocytes/ macrophages into CNS [20, 21] . We measured plasma MCP-1 as a comparator biomarker for this DKK1 study. Plasma MCP-1 levels were higher among HIV þ than HIV À study participants (mean 208 pg/ml vs. 173 pg/ml; P ¼ 0.02; Fig. 3a) . In contrast to DKK1, MCP-1 levels were not associated with GDS or NCI either in the entire group (Fig. 3b) , in the HIV þ subgroup (Fig. 3c) , or in those with HIV RNA 50 copies/ml or less (Fig. 3d) . A receiver operator characteristic curve failed to identify a diagnostically useful threshold value for MCP-1 (238 pg/ml: sensitivity 69.2%, specificity 30.8%, positive predictive value 50.0%).
Discussion
HIV invades the CNS within 2 weeks of infection and sets the stage for inflammation and dysregulation in the brain that ultimately leads to HAND in a substantial proportion of HIV þ adults. Although HAND may take years to present, advances in neuroimaging techniques demonstrate considerable loss in brain volume as early as a year after HIV infection [22] . Neuroimaging (e.g. functional magnetic resonance imaging and PET) is expensive, underscoring the need for biomarkers of HAND which R study participants on ART. HIV þ study participants who are on suppressive ART (HIV plasma viral load 50 copies/ml) were grouped as those diagnosed with HAND, based on GDS score, or those without HAND and portioning analysis (DKK1 !735 pg/ml) applied to plasma DKK1 level. P ¼ 0.05 as measured by analysis of covariance. ART, antiretroviral therapy; DKK1, dickkopf-related protein 1; HAND, HIV-associated neurocognitive disorder; GDS, global deficient score. can reveal mechanisms driving HAND, inform therapeutic strategies, and point-of-care monitoring, especially in the settings of limited resources.
Recent data showed that plasma HIV DNA levels are associated with mild NCI [23] as is differential methylation of DNA loci in monocytes [24] . Putative markers such as MCP-1, cerebrospinal fluid albumin, and neopterin correlate with HIV encephalitis (HIV-E) [3] . HIV-E, however, has a clear clinical manifestation that does not require a biomarker, and HIV-E is also less prevalent in the era of ART. Further, other biomarkers that have been linked to ANI/MND such as those reflecting cell stress (e.g. ceramide, sphingomyelin), oxidative stress (e.g. protein carbonyls and hemoxygenase), energy metabolism (e.g. Krebs cycle substrate), and glutamate regulation (e.g. glutamine) require lumbar puncture [3] , which is less practical in the clinical setting than venipuncture. Further, most HIV þ patients experience mild-to-moderate NCI that nonetheless significantly impacts their day-to-day function [3, 25] and ANI has a six-fold odds ratio of predicting symptomatic neurocognitive decline [26] . These ongoing considerations demand biomarkers that are inexpensive and less invasive, which can diagnose or predict the milder forms of HAND.
Although plasma soluble cluster designation (sCD)14 and sCD163 are elevated in ANI/MND, these markers are indicative of monocyte/macrophage inflammation which is well documented in HAND pointing perhaps to global inflammation rather than specific mechanisms driving neuroinflammaton in HAND. Likewise, blood neurofilament light protein was reported to be associated with lower blood CD4 þ T-cell count and HIV-associated dementia and with cognitive functions [27] . Again, although this link points to neuronal injury, it does not inform the mechanisms driving HAND.
We evaluated here a putative soluble biomarker for HAND, DKK1. DKK1 is an antagonist of the canonical Wnt/b-catenin pathway. It binds to Wnt coreceptor LRP5/6 to prevent LRP5/6 interaction with WntFrizzled complexes. DKK1 also reduces cell surface levels of LRP5/6 by binding to Kremen-1 or 2 and triggering the internalization of LRP5/6 from the cell surface. DKK1 is a potential biomarker for ankylosing spondylitis [28] and osteoarthritis [29] , as well as cancers [30] . In our study, the association between DKK1 and NCI points to dysregulation of Wnt signaling as a critical mechanism driving HAND. This revelation can set the stage for novel therapeutic to target normalization of Wnt signaling as a novel therapeutic strategy in HAND.
We showed here that plasma DKK1 levels could serve as a biomarker for HAND. Plasma DKK1 levels were not correlated with HIV status. However, among HIV þ study participants, cognitively impaired study participants have significantly higher levels of plasma DKK1 than unimpaired study participants. Even in this small sample, the clinically relevant subgroup of HIV þ participants who had suppressed HIV RNA and DKK1 levels more than 735 pg/ml had a high positive predictive value for NCI. Importantly, in the current study the association between elevated DKK1 and HAND did not significantly weaken after accounting for several influential characteristics. In contrast, MCP-1, a biomarker comparator in this analysis, was not associated with NCI. Moreover, the high positive predictive value and high specificity suggest that DKK1 may be useful to screen for elevated HAND risk, providing that the current study results can be replicated in a larger sample.
The mechanism by which DKK-1 is associated with NCI is best studied using in-vitro and/or animal models. DKK1 antagonizes Wnt signaling. Extensive studies from our laboratory have shown that Wnt/b-catenin signaling has two important effects relevant to HIV: it elevates the restriction to productive HIV replication in astrocytes [10, 31, 32] and it enhances HIV replication in a number of susceptible target cells [9, 11] . However, in era of combined antiretroviral therapy, DKK1 effects on inhibiting Wnt/b-catenin to enhance HIV replication is probably not a major player in our reported association HIV-associated neurocognitive disorder Yu et al. 1383 between DKK1 and NCI. Wnt/b-catenin is critical for neuronal-astrocyte communication specifically at the interface of glutamate/glutamine cycle whereby glutamate released from neurons is taken up through EAAT-2 on astrocytes and converted to glutamine by the enzyme glutamine synthetase and subsequently released to be taken up by neurons to be converted back to glutamate. Astrocytes perform 90% of glutamate uptake in the brain. We showed that Wnt/b-catenin regulates the transcriptional expression of both EAAT-2 and glutamine synthetase [15] . Therefore, disruption in Wnt/b-catenin signaling would shut down this cycle. Consequently, as DKK1 antagonizes Wnt/b-catenin signaling it could disrupt this important cycle leading to excessive glutamate, which is reported in HAND and is neurotoxic. Further, we showed that disruption in Wnt/b-catenin leads to astrocyte senescence [33] . DKK1 itself is a target gene of Wnt/b-catenin. Therefore, signals that disrupt Wnt/b-catenin such as interferon (IFN)g or HIV could lead to excessive DKK1 that in turn feedback to further down regulate Wnt/b-catenin signaling [12, 32] . Alternatively, DKK1 may be a response to neuronal injury to mediate synaptic remodeling in response to neuronal injury. However, animal models and in-vitro studies seem to indicate that elevated DKK1 actually leads to neuron degeneration and not repair. Specifically, expression of DKK1 was required in the ischemic and excitotoxicity neuronal death [34] and DKK1 treatment causes degeneration of the excitatory synapses in in-vitro hippocampus slice culture [16] . Further, in an inducible DKK1 transgenic mouse model, DKK1 expression in striatum caused degeneration of corticostriatal glutamatergic synapses and decrease in D1 and D2 dopamine receptor clusters, and impaired striatal-regulated behaviors, for example, a failure to respond to amphetamine stimulation [35] . In-vivo infusion of DKK1 into mouse hippocampus caused cognitive impairment/object cognitive memory consolidation [36] . Further, DKK1 inhibits neurogenesis in brain, suggesting that its elevation is not likely to be a response to neuronal injury but perhaps a facilitator to this injury [37] [38] . The source of plasma DKK1 is rather intriguing, is it leaking out of the brain because of compromised blood-brain barrier integrity in context of HIV or does it reflect a peripheral inflammation that impairs neuronal/glial health. Recent studies show that platelets are a major source of DKK1 in blood [39] . Future studies should address source of DKK1 and mechanism by which it is linked to NCI.
Collectively, our data suggests that DKK1 is a promising biomarker for HAND that may be distinct from those that reflect monocyte activation (e.g., MCP-1). Larger, longitudinal studies are warranted to assess whether DKK1 is a prognostic biomarker for HAND progression. Nonetheless, our findings provide intriguing human data that support substantial in-vitro and animal experimental data on DKK1 and Wnt signaling in neurodegenerative disorders.
